Press Releases

Sanofi Ventures has announced an additional $625 million multi-year capital commitment from Sanofi, increasing its total assets under management to over $1.4 billion. This new commitment to the evergreen venture fund builds on more than a decade of investing in innovative biotech and digital health companies that align with Sanofi’s long-term growth ambitions. “This new, significant capital commitment reflects our strong belief that some of the most important medical bre

BioLegacy Evaluative Group, Inc., a wholly-owned subsidiary of Branded Legacy Inc. (OTC: BLEG) and an emerging leader in life sciences innovation, proudly announces the official opening of its state-of-the-art 22,000-square-foot Good Manufacturing Practice (GMP) facility in Vancouver, Canada. This milestone, following the recent acquisition of the facility, establishes BLEG as a leader in developing innovative, low-cost inhaled naloxone devices to combat the escalating opioid overdose crisis.

GC Biopharma (006280.KS), a leading South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) in South Korea for a Phase 1 clinical trial of "GC4006A," its mRNA (messenger RNA) vaccine candidate for COVID-19. The development of GC4006A has progressed rapidly since April 2025, when the Korea Disease Control and Prevention Agency (KDCA) selected GC Biopharma to lead

Galux, a South Korea–based biotech company pioneering AI-driven protein therapeutics design, today announced new results that further validate its de novo antibody design platform, GaluxDesign. The findings showcase the platform's ability to generate novel antibodies that meet precise structural and functional requirements with atomic-level precision across a broad range of targets. In March, Galux announced antibody designs for six therapeutic targets, at that time one of

Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, today announced receipt of the first milestone payment in the ongoing commercialization of a human papillomavirus (HPV) vaccine in collaboration with SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure. This milestone marks the successful completion and demonstration of a t

NurExone Biologic Inc. a biopharmaceutical innovator in exosome-based regenerative therapies, is pleased to announce that its U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), is planning to establish its first U.S. commercial exosome production facility in Indianapolis, Indiana. The Indianapolis facility would serve as Exo-Top’s U.S. manufacturing base, transferring NurExone’s proprietary exosome production process into the American market. The GMP compliant s

Celltrion Pharm a South Korean biopharmaceutical firm, said on September 16 that it has inked a strategic trilateral agreement with a multinational syringe manufacturer, Becton Dickinson France S.A.S. (BD), and its Korean branch BD Korea. The signing ceremony took place at Celltrion Pharm’s research center in Songdo, Incheon, with its President Yoo Young-ho in attendance alongside key officials from BD and BD Korea. Under the three-way agreement, Celltrion Pharm will establish

Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the Gibco™ Efficient-Pro™ Medium (+) Insulin, a next-generation medium designed to increase titers to maximize productivity and elevate the performance of insulin-dependent CHO cell lines. Efficient-Pro Medium (+) Insulin is the latest addition to Thermo Fisher’s existing Efficient-Pro medium and feed system, designed to provide optimized growth and productivity for insulin-dependent CHO cell

Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc's clinical drug candidate discovered from Oncology One's out-licensed KAT6 inhibitor program, has now commenced a Phase 3 clinical trial, a key milestone. Quick facts: PF-07248144 is a selective catalytic inhibitor of KAT6 (KAT6A/B), members of the histone lysine acetyltransferase family of enzymes that are involved in regulating gene e

Absci, a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to accelerate generative AI-driven drug discovery. Absci’s generative AI Drug Creation Platform leverages OCI’s AI infrastructure and AMD’s latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles. To advance Absci’s mission of creating better bi